Trial Profile
An observational, retrospective, multicenter and comparison study of sunitinib in patients with metastatic renal carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 11 Aug 2016 New trial record